| 发明名称 |
Use of Reslizumab To Treat Moderate to Severe Eosinophilic Asthma |
| 摘要 |
Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL; and 2) administering to said patient a therapeutically effective dose of reslizumab. |
| 申请公布号 |
US2016102144(A1) |
申请公布日期 |
2016.04.14 |
| 申请号 |
US201514838503 |
申请日期 |
2015.08.28 |
| 申请人 |
O'Brien Christopher;Zangrilli James;Shah Tushar;Brusselle Guy |
发明人 |
O'Brien Christopher;Zangrilli James;Shah Tushar;Brusselle Guy |
| 分类号 |
C07K16/24;A61K9/00 |
主分类号 |
C07K16/24 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating moderate to severe eosinophilic asthma in a patient comprising:
identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μl; and administering to said patient a therapeutically effective dose of reslizumab. |
| 地址 |
Lafayette Hill PA US |
